

MATERIAL CHANGE REPORT

PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102

1. **Name and Address of Company:**

Miraculins Inc. (the "Company")
6 – 1250 Waverley Street
Winnipeg, Manitoba
R3T 6C6

2. **Date of Material Change:**

October 26, 2015

3. **News Release:**

The Company issued a press release regarding the material change on October 26, 2015, a copy of which is attached hereto.

4. **Summary of Material Change:**

On October 26, 2015, the Company completed the first closing of a non-brokered private placement offering (the "Offering") of up to 5,000,000 units ("Units") at a price of \$0.05 per Unit for gross proceeds of up to \$250,000. Each Unit is comprised of one common share of the Company (a "Share") and one-half of one Share purchase warrant. Each whole warrant (a "Warrant") entitles the holder to purchase one Share at a price of \$0.08 per Share for a period of 12 months from the date the Warrant is issued. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws. The first closing brought in aggregate gross proceeds of \$135,000 from the sale of 2,700,000 Units.

5. **Full Description Of Material Change:**

See attached Schedule "A".

6. **Reliance on subsection 7.1(2) or (3) of National Instrument 51-102:**

Not Applicable.

7. **Omitted Information:**

Not Applicable.

8. **Executive Officer:**

Christopher Moreau, Chief Executive Officer
Tel: (204) 477-7599

DATED at Winnipeg, Manitoba this 13th day of November, 2015.

MIRACULINS INC.

Per: ^{*“Christopher Moreau”*}
Christopher Moreau, President and
CEO

SCHEDULE "A"

Miraculins Announces First Closing of Private Placement Offering

WINNIPEG, Manitoba – October 26, 2015 - Miraculins Inc. (TSX-V:MOM) (the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, today announces the first closing of a non-brokered private placement offering (the "Offering") of up to 5,000,000 units ("Units") at a price of \$0.05 per Unit for gross proceeds of up to \$250,000. Each Unit is comprised of one common share of the Company (a "Share") and one-half of one Share purchase warrant. Each whole warrant (a "Warrant") entitles the holder to purchase one Share at a price of \$0.08 per Share for a period of 12 months from the date the Warrant is issued. The Shares and Warrants will be restricted from transfer for a period of four months and a day from the date hereof in accordance with applicable securities laws. The first closing brought in aggregate gross proceeds of \$135,000 from the sale of 2,700,000 Units.

A certain person assisted the Company by introducing a subscriber for the Offering and was paid a finder's fee of 10% of the total subscription proceeds received from the subscriber introduced to the Company by that person.

The net proceeds of the Offering will be used for general corporate purposes.

The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.

For more information, please contact:

Christopher J. Moreau
President & CEO
Miraculins Inc.
Ph: 204-477-7599
Fax: 204-453-1546

info@miraculins.com
www.miraculins.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.